← Back to Search

Virus Vaccine

SARS-COV2 Pfizer Vaccine for Coronavirus

Phase < 1
Waitlist Available
Led By Rachna Shroff, MD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

Eligible Conditions
  • Coronavirus
  • Cancer
  • Vaccine Response Impaired

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Immune response
Secondary outcome measures
Adverse events

Trial Design

1Treatment groups
Experimental Treatment
Group I: 3rd COVID-19 vaccine (2nd booster)Experimental Treatment1 Intervention
Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SARS-COV2 Pfizer Vaccine
2021
Completed Early Phase 1
~20

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
514 Previous Clinical Trials
148,251 Total Patients Enrolled
Rachna Shroff, MDPrincipal InvestigatorUniversity of Arizona
1 Previous Clinical Trials
29 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025